{"id":"13c-methacetin","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"13C-Methacetin is a non-invasive diagnostic agent that measures liver function by tracking the metabolism of a methyl-labeled acetaminophen derivative. After oral administration, the drug is metabolized by hepatic cytochrome P450 enzymes, and the resulting 13C-labeled carbon dioxide is exhaled and measured in breath samples, providing a quantitative assessment of hepatic metabolic capacity without requiring blood draws or imaging.","oneSentence":"13C-Methacetin is a stable isotope-labeled tracer used to assess hepatic metabolic function and liver synthetic capacity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:41:47.217Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Assessment of hepatic metabolic function in patients with liver disease"},{"name":"Non-invasive evaluation of liver synthetic capacity and cirrhosis severity"}]},"trialDetails":[{"nctId":"NCT06022588","phase":"NA","title":"Chronic Mesenteric Ischemia Breath Testing","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2021-03-01","conditions":"Chronic Mesenteric Ischemia","enrollment":20},{"nctId":"NCT04176458","phase":"NA","title":"Methacetin Breath Test in Patients With Liver Disease Secondary to Heart Disease","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2019-04-21","conditions":"Dilated Cardiomyopathy, Tricuspid Atresia","enrollment":4},{"nctId":"NCT00736840","phase":"PHASE3","title":"BreathID 13C-Methacetin Breath Test for Detecting Cirrhosis","status":"COMPLETED","sponsor":"Meridian Bioscience, Inc.","startDate":"2008-08","conditions":"Chronic Liver Disease","enrollment":414},{"nctId":"NCT02143778","phase":"NA","title":"Assessing Portal Hypertension With Methacetin Breath Test","status":"COMPLETED","sponsor":"Meridian Bioscience, Inc.","startDate":"2014-11","conditions":"Patients With Compensated Liver Cirrhosis","enrollment":246},{"nctId":"NCT02314026","phase":"PHASE2","title":"BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH","status":"COMPLETED","sponsor":"Meridian Bioscience, Inc.","startDate":"2015-03","conditions":"Non-Alcoholic Steatohepatitis","enrollment":140},{"nctId":"NCT02084160","phase":"","title":"Prediction Value of the BreathID 13C-Methacetin Breath Test for Hepatic Decompensation","status":"COMPLETED","sponsor":"Meridian Bioscience, Inc.","startDate":"2014-03","conditions":"Chronic Liver Disease","enrollment":579},{"nctId":"NCT03611101","phase":"","title":"Companion Protocol for ¹³C-Methacetin Breath Tests in BMS: NCT03486899, NCT03486912 Referenced Trials","status":"COMPLETED","sponsor":"Meridian Bioscience, Inc.","startDate":"2018-05-04","conditions":"NASH - Nonalcoholic Steatohepatitis","enrollment":124},{"nctId":"NCT02786836","phase":"PHASE2, PHASE3","title":"13C-Methacetin Breath Test for the Prediction of Outcome in in ALI or ALF","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2016-06-10","conditions":"Acute Liver Failure","enrollment":76},{"nctId":"NCT00244569","phase":"PHASE3","title":"Development of a Breath Test for Monitoring Patients With Liver Disease","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2005-09","conditions":"Fatty Liver, Cirrhosis","enrollment":120},{"nctId":"NCT01946360","phase":"NA","title":"Role of 13C Methacetin Breath Test in Predicting Prognosis Among Patients With Acute or Acute on Chronic Liver Failure (ACLF).","status":"COMPLETED","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2014-04","conditions":"Acute Liver Failure, Acute on Chronic Liver Failure","enrollment":24},{"nctId":"NCT01157845","phase":"PHASE3","title":"Use of Methacetin Breath Test to Predict Liver Failure in Patients With Cirrhosis","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2010-03","conditions":"Cirrhosis","enrollment":165},{"nctId":"NCT01204827","phase":"PHASE2, PHASE3","title":"Follow Up of Patients Chronic Hepatitis B (CHB) Treated With Sebivo Using the 13C Methacetin Breath Test","status":"WITHDRAWN","sponsor":"Hadassah Medical Organization","startDate":"","conditions":"Chronic Hepatitis B","enrollment":""},{"nctId":"NCT01205074","phase":"PHASE2, PHASE3","title":"¹³C-Methacetin Breath Test (MBT) Methodology Study","status":"UNKNOWN","sponsor":"Hadassah Medical Organization","startDate":"2010-09","conditions":"Healthy Subjects, Chronic Liver Disease, Cirrhosis","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":65,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["N-(4)-13Cmethoxyphenyl acetamide"],"phase":"phase_3","status":"active","brandName":"13C-Methacetin","genericName":"13C-Methacetin","companyName":"University of Texas Southwestern Medical Center","companyId":"university-of-texas-southwestern-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"13C-Methacetin is a stable isotope-labeled tracer used to assess hepatic metabolic function and liver synthetic capacity. Used for Assessment of hepatic metabolic function in patients with liver disease, Non-invasive evaluation of liver synthetic capacity and cirrhosis severity.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}